Researchers at Moffitt Cancer Center have discovered a unique immune gene signature that can predict the presence of microscopic lymph node-like structures in metastatic melanoma. The presence of these immune structures, the researchers said, appears to be associated with better survival and may indicate the possibility of selecting patients for immunotherapy based solely on the immune-related makeup of their tumors as an approach to personalized medicine.
[More]
The key to restoring production of insulin in type I diabetic patients, previously known as juvenile diabetes, may be in recovering the population of protective cells known T regulatory cells in the lymph nodes at the "gates" of the pancreas, a new preclinical study published online October 8 in Cellular & Molecular Immunology by researchers in the Department of Bioscience Technologies at Thomas Jefferson University suggests.
[More]
NOXXON Pharma today announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa clinical trial of its anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer NOX-A12.
[More]
The process of metastasis, by which cancer cells travel from a tumor site and proliferate at other sites in the body, is a serious threat to cancer patients. According to the National Cancer Institute, most recurrences of cancer are metastases rather than "new" cancers.
[More]
Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, today announced top line results from a clinical study showing that the novel inhaled therapeutic, PUR118, demonstrated anti-inflammatory efficacy and was well-tolerated in two Phase 1b studies in patients with chronic obstructive pulmonary disease (COPD).
[More]
BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.
[More]
Scientists are trying to open a new front in the battle against gum disease, the leading cause of tooth loss in adults and sometimes termed the most serious oral health problem of the 21st century. They described another treatment approach for the condition in a report here today at the 244th National Meeting & Exposition of the American Chemical Society, the world's largest scientific society.
[More]
Tissue implants made of cells grown on a sponge-like scaffold have been shown in clinical trials to help heal arteries scarred by atherosclerosis and other vascular diseases. However, it has been unclear why some implants work better than others.
[More]
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine.
[More]
Biokine Therapeutics Ltd. announced today that it has received Orphan Drug designation from the US Food and Drug Administration (FDA) for the mobilization of hematopoietic stem cells from bone marrow into peripheral blood for collection and subsequent transplantation in patients with hematological cancers.
[More]
It is not primary tumors that are responsible for the majority of cancer deaths, but rather their metastases. Physiologists and neuropathologists from the University of Zurich have now identified the origin of metastasis formation, thereby becoming the first to reveal the pathway of metastasizing intestinal cancer cells out of the blood stream. The results allow new approaches in the development of cancer therapies.
[More]
NOXXON Pharma today announced the treatment of the first cohort of three chronic lymphocytic leukemia (CLL) patients in a Phase IIa clinical trial of its NOX-A12 anti-CXCL12/SDF-1 (CXC Chemokine Ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer.
[More]
How does a tumor cell set up a signaling pathway in order to metastasize? Scientists at Technische Universit-t M-nchen's (TUM) Klinikum rechts der Isar and Helmholtz Zentrum M-nchen have made a significant discovery in this area by studying colon cancer.
[More]
Researchers at NYU School of Medicine have made an important discovery that partially answers the long-standing question of why a mother's immune system does not reject a developing fetus as foreign tissue.
[More]
The HIV drugs known as CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing, researchers from the Kimmel Cancer Center at Jefferson suggest in a preclinical study published in a recent issue of Cancer Research.
[More]
Scientists have identified a new HIV-suppressing protein in the blood of people infected with the virus. In laboratory studies, the protein, called CXCL4 or PF-4, binds to HIV such that it cannot attach to or enter a human cell.
[More]
By pairing an intimate knowledge of immune-system function with a deep understanding of statistical physics, a cross-disciplinary team at the University of Pennsylvania has arrived at a surprising finding: T cells use a movement strategy to track down parasites that is similar to strategies that predators such as monkeys, sharks and blue-fin tuna use to hunt their prey.
[More]
Recent work in mice suggested that the immune system is involved in removing beta-amyloid, the main Alzheimer's-causing substance in the brain. Researchers have now shown for the first time that this may apply in humans.
[More]
Innate differences in immunity can be detected at birth, according to new research at Washington University School of Medicine in St. Louis. And babies with a better innate response to viruses have fewer respiratory illnesses in the first year of life.
[More]
Scientists at Indiana University Health's Cancer Research Laboratory have found that a sophisticated botanical formula slows human breast cancer growth and inhibits breast to lung metastasis in mice. The formula contains extracts from medicinal mushrooms, medicinal herbs and purified nutritional compounds, and showed no toxic side-effects.
[More]